|
|
发表于 14-5-2009 12:43 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 14-5-2009 06:17 PM
|
显示全部楼层
原帖由 m.i.k.e 于 14-5-2009 12:32 PM 发表 
大家谈的是 CTIC, 不是CitiBank.
原来如此。。。。 blueberry1 兄， ｂｌｕｅ 就好了不要ｂｌｕｒ．．．
对了， 有谁知道ｐｉｘ 的ｒｅｓｕｌｔ 几时会公布吗？ |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-5-2009 08:28 PM
|
显示全部楼层
原帖由 Gnoit 于 14-5-2009 12:12 PM 发表 
USD3.4????
昨晚排了1。20 ， 买不到， 今晚再排吧！
据我所了解，它的pix 已经在fda 试验着但需要6 个月来观察，所以他的result 要在年尾才知道， 对吗？
那我们至少要收半年哦。。。
FDA 的 result 是今年年尾。。。
可是 EUROPE...可能在这几个月。。。。
这次的涨幅也是因为 europe 有真人来试验这药。。。
照理。。。europe check 得更严。。。europe 过， FDA９０％ 过。。。
现在等着吧。。。
６月可能还有一场 重头戏。。。。
去前业 我所说的 ｆａｎｓ 网站 有提到。。。 |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-5-2009 08:29 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-5-2009 08:32 PM
|
显示全部楼层
http://news.prnewswire.com/ViewC ... 05025888&EDATE=
Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
SEATTLE, May 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 2009 BIO International Convention at the Georgia International Convention Center in Atlanta, Georgia, on Tuesday, May 19th at 10:40 AM in Room 311 of Building A, Level 3.
2009 BIO International Convention
CTI Presentation: Tuesday, May 19, 2009
10:40 AM Eastern/4:40 PM Central European/7:40 AM Pacific
Georgia International Convention Center
Room 311, Building A, Level 3
Media Contact: Investors Contact:
Cell Therapeutics, Inc. Cell Therapeutics, Inc.
Dan Eramian Ed Bell
T: 206.272.4343 T: 206.272.4345
F: 206.272.4434 Lindsey Jesch Logan
E: media@ctiseattle.com T: 206.272.4347
www.celltherapeutics.com/press_room F: 206.272.4434
E: invest@ctiseattle.com
www.celltherapeutics.com/investors |
|
|
|
|
|
|
|
|
|
|
|
发表于 14-5-2009 10:12 PM
|
显示全部楼层
这几天股价一直在跌～～想买的人可以再伺机进货。只要FDA通过，大家就赚大钱了～～
我也是买了500unit @ usd1.21。。。
大家呢？ |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 07:32 AM
|
显示全部楼层
http://www.abstract.asco.org/AbstView_65_35306.html
Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma.
Sub-category: Lymphoma
Category: Lymphoma and Plasma Cell Disorders
Meeting: 2009 ASCO Annual Meeting
Citation: J Clin Oncol 27:7s, 2009 (suppl; abstr 8523)
Abstract No: 8523
Abstract:
Background: Currently, treatment options for multiply relapsed aggressive NHL are limited, and response rates are disappointing. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone, has potentially reduced cardiotoxicity and has demonstrated promising clinical activity in phase II studies in heavily pretreated NHL patients. Methods: PIX301 was a controlled, multicenter, open-label phase III study of ≥ third-line treatment of relapsed aggressive (de novo or transformed) NHL. All patients were required to have received ≥ 1 prior anthracycline-containing regimen, with the cumulative doxorubicin-equivalent dose limited to ≤ 450 mg/m2. Randomization was to pixantrone 85 mg/m2 on days 1, 8 and 15 of 28-day cycles, for up to 6 cycles, or to investigator's choice of a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, or mitoxantrone; in the US only, gemcitabine and rituximab were permitted). The primary study endpoint was CR/CRu rate. Secondary objectives included safety, OS, and ORR. Originally planned to enroll 320 patients, PIX301 was amended to 140 patients due to slow enrollment. Results: 140 patients (70 per arm) were randomized. Median age was 60 on the pixantrone arm, 58 on the control arm; patients on both arms had received a median of 3 prior chemotherapeutic regimens. Based on independent review in the ITT population, the CR/CRu rate in patients treated with pixantrone was significantly higher than in those receiving other agents (20.0% vs. 5.7%, p-value = 0.02), and there were no CRs in the control group compared to 8 CRs in the pixantrone group.
Conclusions: In this study, single-agent therapy with pixantrone achieved significantly superior CR/CRu and ORR rates in ≥ third-line treatment of relapsed/refractory aggressive NHL.
--------------------------------------------------------------------------------
Response Rates and Number of Responses by Independent Review (ITT population)
--------------------------------------------------------------------------------
Pixantrone (n=70) Control (n=70) P value
CR/CRu 20% (14) 5.7% (4) p=0.021
ORR 37% (26) 14.3% (10) p=0.003
--------------------------------------------------------------------------------
ORR = objective response rate
CR =Complete remission |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 08:51 AM
|
显示全部楼层
那个conclusion是他们自己写的。。。。
[ 本帖最后由 bennywt 于 15-5-2009 09:35 AM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 10:38 AM
|
显示全部楼层
昨天买了1000 usd 1.21, 一买就跌了，  。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 11:21 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 11:46 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 12:55 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 01:13 PM
|
显示全部楼层
原帖由 Gnoit 于 15-5-2009 11:46 AM 发表 
为什么出货呢？不要用这股来买卖短期。。。
hold 到药的result 为止。 我们买这股是aim 1000% return的， 短期波动就别理他啦。。。
当你买的股票在下跌时
你会如何做？
1）放着不关它
2）再买进来拉低本钱
3）卖出，等低才买进
 |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 01:14 PM
|
显示全部楼层
原帖由 kooilieng 于 15-5-2009 12:55 PM 发表
你打算出了再买进？
你猜对了 |
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 01:17 PM
|
显示全部楼层
原帖由 nehooi05 于 2009-5-15 01:14 PM 发表
你猜对了
你之前买什么价钱啊？ |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 15-5-2009 10:38 PM
|
显示全部楼层
原帖由 Gnoit 于 15-5-2009 10:38 AM 发表
昨天买了1000 usd 1.21, 一买就跌了， 。。。
下是因为 坏消息。。。因该是 刻意的！。。。
说 CTIC 只值 ０．２８。。。。
之后出来道歉了。。。。
放心放心。。。。多 几个星期。。。。耐心点。。。。 |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 15-5-2009 10:43 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 15-5-2009 10:53 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 15-5-2009 10:59 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 15-5-2009 11:00 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
）
1990 
35
